Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

NCT06172426•Novartis Pharmaceuticals

Summary

This was a retrospective cohort study to assess the incidence rate of psoriatic arthritis (PsA) among psoriasis (PsO) patients newly initiated on secukinumab or any biologics/apremilast (small molecule). The analysis was performed in two databases, IBM® MarketScan® database: Commercial Claims and Encounters (CCAE) and Medicare Supplemental Beneficiaries (MDCR) from 01 January 2010 to 30 June 2021 and BADBIR from 01 January 2016 to 01 September 2021.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•MarketScan® secukinumab cohort:
•Included patients with at least 1 secukinumab claim between 01 January 2015 and 30 June 2020 (index date is the first secukinumab claim)
•Included patients age ≥18 years as of the year of index date
•Included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period
•Included patients with continuous medical/pharmacy coverage in the 2-year pre-index period
•Included patients with continuous medical/pharmacy coverage in the 1-year post-index period
•Included non-switched patients with secukinumab treatment on or after the enrollment between 01 January 2017 to 01 September 2020
•* Non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date
•* Index date will be the date of the first secukinumab treatment date
•Included patients with age ≥ 18 on the index date
+3 more criteria

Exclusion Criteria

•Excluded patients with any psoriatic arthritis diagnosis during 2 years to 5 years pre-index period, as well as on the index date
•Excluded patients with any biologics/apremilast including secukinumab claim during the 2-year pre-index (excluding index date)
•Excluded patients received other non-secukinumab biologics/apremilast during 6 months post index date period (including index date) (This criterion is only applicable for the secukinumab cohort)
•BADBIR cohort:
•Excluded patients with psoriatic arthritis (PsA) prior to and on index date
•Excluded patients with any biologics/apremilast including secukinumab in the baseline period

Locations (1)

Novartis

Basel, Switzerland

Key Dates

Start Date

November 17, 2022

Primary Completion Date

December 7, 2022

Completion Date

December 7, 2022

Last Updated

December 15, 2023

Enrollment

1,171

ACTUAL participants

Conditions

Psoriatic ArthritisPsoriasis

A Study of Picankibart in Patients With Active Psoriatic Arthritis

NCT07295509

Psoriatic Arthritis

View study

RECRUITING

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 15, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

Inclusion Criteria

Exclusion Criteria

A Study of Picankibart in Patients With Active Psoriatic Arthritis

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis